CAR T-Cell Therapy for Non-Hodgkin Lymphoma | Cancer Q&A — Discussing Common Questions Posed by Patients
Hematologic Oncology Update
00:00
Mechanisms of resistance and next‑gen CARs
Jeremy explains antigen loss, T‑cell exhaustion, and strategies like dual targeting and allogeneic CARs.
Play episode from 40:05
Transcript
